Krish Patel

Director, Hematologic Malignancies and Cellular Therapy at Swedish Cancer Institute
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Seattle, Washington, United States, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Credentials

  • Hematology
    American Board of Internal Medicine
    Oct, 2017
    - Nov, 2024
  • Medical Oncology
    American Board of Internal Medicine
    Oct, 2016
    - Nov, 2024
  • ABIM Internal Medicine
    -

Experience

    • United States
    • Hospitals and Health Care
    • 1 - 100 Employee
    • Director, Hematologic Malignancies and Cellular Therapy
      • Jan 2022 - Present

    • Director of Lymphoma Program
      • Apr 2019 - Present

    • Physician/Clinical Investigator, Hematologic Malignancies and Cellular Therapy
      • Jul 2016 - Present

      Lymphoma physician and clinical investigator at Center for Blood Disorders and Stem Cell Transplantation.

    • Hospitals and Health Care
    • 700 & Above Employee
    • Hematology/Oncology Fellow
      • Jul 2012 - Jun 2016

    • Chief Resident, Internal Medicine
      • Jul 2013 - Jun 2014

    • Hospitals and Health Care
    • 700 & Above Employee
    • Resident Physician - Internal Medicine
      • Jun 2009 - Jun 2012

    • United States
    • Biotechnology Research
    • 700 & Above Employee
    • CRTP Fellow
      • Aug 2007 - Aug 2008

      Research Fellow in the Gius Lab at the NCI/NIH. Elaborated a novel model relating cellular aging and mitochondrial dysfunction to oncogenesis. Research Fellow in the Gius Lab at the NCI/NIH. Elaborated a novel model relating cellular aging and mitochondrial dysfunction to oncogenesis.

Education

  • Duke University School of Medicine
    MD
    2005 - 2009
  • Duke University
    B.S., Biology, Pharmacology
    2001 - 2005

Community

You need to have a working account to view this content. Click here to join now